Background. Lefamulin, a pleuromutilin antibiotic, is active against pathogens commonly causing community-acquired bacterial pneumonia (CABP). The Lefamulin Evaluation Against Pneumonia (LEAP 1) study was a global noninferiority trial to evaluate the efficacy and safety of lefamulin for the treatment of CABP.
and oral dosing regimens used in the clinical trials achieve comparable drug exposures. The drug achieves rapid and predictable penetration into human tissues, with a mean 5.7-fold higher concentration in the pulmonary epithelial lining fluid, compared with plasma [20, 21] .
The Lefamulin Evaluation Against Pneumonia (LEAP 1) study evaluated the efficacy and safety of IV-to-oral lefamulin monotherapy, as compared with moxifloxacin ± linezolid (hereafter referred to as "moxifloxacin") in adults with CABP.
METHODS

Study Design and Conduct
In this Phase III, multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group study (NCT02559310), participating centers obtained study approval from their institutional review boards/ethics committees; all patients provided written informed consent before any study procedure. The study was compliant with ethical principles aligned with the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations.
Study Population
Patients ≥18 years fulfilled the US Food and Drug Administration (FDA) entry criteria for CABP trials [22] , including having radiographic findings suggestive of pneumonia, Pneumonia Outcomes Research Team (PORT) risk classes ≥III (Supplementary Methods 1), acute illness (≤7 days), and ≥3 CABP symptoms (dyspnea, new or increased cough, purulent sputum production, chest pain); ≥25% of patients enrolled were to be PORT class IV or V. Exclusion criteria included the receipt of prior antibiotics for the current illness; ≤25% of randomized patients could have received a single dose of a short-acting antibiotic. The Supplementary Methods 2 detail complete inclusion/exclusion criteria.
Randomization and Intervention
Patients were randomized 1:1 to receive lefamulin at 150 mg IV every 12 hours (q12h) or moxifloxacin at 400 mg IV every 24 hours (q24h). Moxifloxacin-treated patients received alternating doses of a placebo to maintain blinding. On or after 3 days (6 doses) of IV treatment, patients could be switched to oral lefamulin at 600 mg q12h or moxifloxacin at 400 mg q24h if predefined criteria were met (Supplementary Methods 3). If MRSA was suspected at screening, blinded linezolid at 600 mg IV q12h was added to moxifloxacin and a linezolid placebo was added to lefamulin (Supplementary Methods 4). If a baseline culture did not confirm MRSA, the linezolid/linezolid placebo was discontinued.
Treatment duration ranged from 5-10 days. In the initial protocol, patients with CABP due to MRSA or L. pneumophila and patients with S. pneumoniae with accompanying bacteremia received 10 days of active treatment. Otherwise, lefamulin-treated patients received 5 days of active therapy and moxifloxacin-treated patients received 7 days of active therapy. A protocol amendment changed the therapy duration to 7 days for both groups, except in patients with MRSA, who received 10 days of active therapy. The amendment was consistent with professional society guidelines and was implemented to simplify the study drug administration procedures.
Study Evaluations and Endpoints
Patients were evaluated at the early clinical assessment, end of treatment, test of cure (TOC), and late follow-up visits. The FDA primary endpoint was the early clinical response (ECR) responder rate in the intent-to-treat (ITT) population at 96 ± 24 hours after the first study drug dose (Table 1) . ECR responders showed improvement in ≥2 CABP signs/symptoms, had no worsening in any CABP sign/symptom, and had not received a concomitant, nonstudy antibiotic for CABP. The European Medicines Agency (EMA) co-primary endpoint was an investigator assessment of clinical response (IACR) at TOC (5-10 days after last study drug dose) in the modified ITT (mITT) and clinically evaluable (CE) populations (Table 1) . IACR was classified as successful if CABP signs/ symptoms resolved or improved such that no additional antibacterial therapy was administered for CABP. Additional endpoints included ECR and IACR by pathogen in the microbiological ITT (microITT; defined as patients with ≥1 baseline pathogen) and microITT-2 (defined as patients with ≥1 baseline pathogen identified by methodology other than polymerase chain reaction [PCR]) populations.
Safety assessments included treatment-emergent adverse events (TEAEs), clinical laboratory parameters, and vital signs. Triplicate 12-lead electrocardiograms were performed on Days 1 and 3.
Causative pathogens were identified by respiratory or blood sample cultures, quantitative real-time PCR, serology, or urine antigen testing, using a specimen collected within ±24 hours of the first study drug dose (Supplementary Methods 5). Strains were isolated at a local laboratory and confirmed at a central laboratory.
Statistical Analyses
The study was designed to have sufficient power for both the FDA and EMA primary analyses. Assuming IACR success rates of 80% and 85% in the mITT and CE populations [23] , respectively, and an 80% clinical evaluability rate, 550 patients provided 80% power for the demonstration of noninferiority for IACR at TOC, using a 10% noninferiority margin and a 1-sided alpha of 0.025. Utilizing a 79% ECR responder rate in the ITT population [24] and a 1-sided alpha of 0.025, a sample size of 550 patients provided >90% power to establish the noninferiority of lefamulin, using a 12.5% margin. Margins of 12.5% for ECR and 10% for IACR were based on current FDA [22] and EMA guidance [25] , respectively. A 2-sided 95% confidence interval (CI), calculated using a continuity-corrected Z-statistic for the difference in ECR responder rates in the ITT population, was used to test for the noninferiority of lefamulin versus moxifloxacin. Noninferiority was concluded if the lower limit of the 95% CI for treatment difference exceeded -12.5%. For IACR, a 2-sided 95% CI was used, calculated using the Miettinen and Nurminen method, with stratification for the randomization stratification factors (PORT risk class, region, and receipt of a single dose of a short-acting antibiotic). Noninferiority was concluded if the lower limit of the 95% CI for treatment difference exceeded -10% for both the mITT and CE populations. Given that the 2 primary endpoints were analyzed separately for the regulatory agencies, no adjustment for multiple comparisons was required. The 95% CIs for treatment differences for additional analyses were calculated using the same methodology as for ECR [22, 25] .
RESULTS
Patients
This study enrolled 551 patients at 66 centers across 18 countries between February 2016 and May 2017 ( Figure 1 ). Approximately 25% of patients were enrolled before the protocol amendment noted above. Demographics and baseline characteristics were generally well balanced between treatment groups (Table 2) , with the noted exception that 47.8% and 39.3% of patients were aged ≥65 years in the lefamulin and moxifloxacin groups, respectively. Table 1 describes the calculation of the study drug treatment duration; a single dose of a study drug on a calendar day counted as a full day of treatment. In the safety analysis set, the median (range) study drug treatment (IV and oral) duration was 7 (1-11) days for lefamulin and 7 (1-10) days for moxifloxacin. The median (range) IV therapy duration was 7 (1-11) days for lefamulin and 6 (1-10) days for moxifloxacin, and the median (range) oral therapy duration was 4 (1-7) and 4 (1-5) days, respectively. In lefamulin-treated patients, 38.1% (104/273) of patients switched from IV to oral therapy, compared with 44.3% (121/273) in moxifloxacin-treated patients.
The baseline pathogen distribution was similar between the treatment groups (Table 3) . Streptococcus pneumoniae was the most commonly isolated pathogen. Most H. influenzae and M. catarrhalis isolates were detected by PCR, producing higher incidences in the microITT versus microITT-2 population. At baseline, MRSA was suspected in 23 patients (9 treated with lefamulin; 14 treated with moxifloxacin), but no case was confirmed. Both drugs were active in vitro against the most commonly isolated pathogens (Table 4 ).
Efficacy Outcomes
Clinical Response/Success: Early Clinical Response and Investigator Assessment of Clinical Response
Lefamulin demonstrated noninferiority to moxifloxacin for both the FDA primary endpoint of ECR ( Figure 2A ) and the EMA primary endpoint ( Figure 2B ) of IACR. Results were consistent under the original protocol and the revised protocol ( Supplementary Figure 1 ).
Clinical Response/Success by Baseline Pathogen
In the microITT population (Table 5 ), lefamulin and moxifloxacin demonstrated similar ECR responder and IACR success rates across all baseline CABP pathogens. The microITT-2 population also showed similar responder/success rates across baseline pathogens, but had more variability than the microITT population, due to smaller sample sizes.
Baseline bacteremia occurred in 2.5% (7/276) of patients randomized to lefamulin (6 S. pneumoniae; 1 S. aureus) and 1.1% (3/275) randomized to moxifloxacin (2 Escherichia coli; 1 Burkholderia cepacia). Among these, 4 of 7 lefamulin-treated patients and 2 of 3 moxifloxacin-treated patients were ECR responders. For IACR at TOC, 1 of 7 lefamulin recipients and 2 of 3 moxifloxacin recipients achieved treatment success. Of the 6 lefamulin-treated patients with pneumococcal bacteremia, 1 achieved treatment success, while 5 were treatment failures for IACR at TOC. Of the treatment failures, 1 patient died on Day 3, due to respiratory failure, while the other 4 patients had confounding factors: 2 had pleural empyema, requiring prolonged therapy beyond the study period; 1 discontinued on Day 3 due to bradycardia; and 1 had improved symptoms but persistent fever, for which the investigator continued antibiotic therapy beyond Table 1 for definitions of the patient populations. Abbreviations: CABP, community-acquired bacterial pneumonia; CE, clinically evaluable; IACR, investigator assessment of clinical response; ITT, intent-to-treat; microITT, microbiological ITT; microITT-2, microbiological ITT-2; mITT, modified ITT; MRSA, methicillin-resistant Staphylococcus aureus; TOC, test of cure. a Met the criteria for CABP, received at least the prespecified minimal amount of the intended dose of the study drug and minimum duration of treatment, IACR not indeterminate, did not receive a concomitant antibacterial therapy (other than adjunctive linezolid) that is potentially effective against CABP pathogens (except in the case of clinical failure), and had no other confounding factors that interfered with the outcome assessment.
the study period. After the completion of 11 days of lefamulin, the patient with S. aureus infection improved, but received additional antibiotics for hemoptysis and was diagnosed with endobronchial diverticulitis; the patient was a responder based on ECR but an IACR failure based on the need for additional antibiotics. No patient with bacteremia had follow-up blood cultures. The microITT group consisted of all patients in the ITT analysis set who had ≥1 baseline pathogen detected. The microITT-2 group consisted of all patients in the ITT analysis set who had ≥1 baseline pathogen detected by diagnostic means other than polymerase chain reaction. 
Abbreviations
Clinical Response/Success by Subpopulations
Lefamulin and moxifloxacin demonstrated high ECR responder and IACR success rates across all CABP severities (Figure 3 ). Figure 4 shows results for other subpopulations. For patients aged <65 years and those meeting modified American Thoracic Society (ATS) severity criteria (baseline presence of ≥3 of the following: respiratory rate ≥30 breaths/min, oxygen saturation <90% or partial pressure of arterial oxygen <60 mmHg, blood urea nitrogen ≥20 mg/dL, white blood cell count <4000 cells/mm 3 , confusion, multilobar infiltrates, platelet count <100 000 cells/mm 3 , temperature <36°C, and systolic blood pressure <90 mmHg), the treatment differences favored moxifloxacin. Further analyses indicated that the lower response rate among patients <65 years was confounded by minor, not major, ATS severity criteria. When analyzed by the presence of minor ATS severity criteria, response rates among patients <65 years were lower among lefamulin-treated patients versus moxifloxacintreated patients. However, for patients aged <65 years who did not meet minor ATS severity criteria, there was no difference between the treatment groups in efficacy (ECR or IACR; Supplementary Table 1 ). ATS variables associated with treatment group differences were not identifiable by logistic regression models (data on file).
Safety and Tolerability
Rates of TEAEs, most of which were mild or moderate in severity, were similar between treatment groups ( Table 6 ). The most common TEAEs in lefamulin recipients were hypokalemia, nausea, insomnia, and infusion site pain (each in 2.9% of patients). The most common TEAE in moxifloxacin recipients was diarrhea (7.7%). There was 1 case of angioedema a b Noninferiority of lefamulin for the EMA co-primary endpoints was concluded if the lower limit of the 2-sided 95% CI for the observed difference in IACR success rates between the treatment groups was greater than −10% for both the mITT and CE populations. in the group of moxifloxacin-treated patients, but none in the lefamulin-treated patients.
Fewer gastrointestinal system organ class TEAEs were reported with lefamulin than moxifloxacin (6.6% vs 13.6%, respectively; 3.7% and 12.1%, respectively, during IV treatment and 7.7% and 5.8%, respectively, during oral treatment). The most common event overall was diarrhea (0.7% lefamulin; 7.7% moxifloxacin). No gastrointestinal TEAE led to a study drug discontinuation, and no Clostridium difficile infections were reported.
Infusion site reactions occurred in 7.7% of lefamulin recipients and 3.7% of moxifloxacin recipients. The most common event was infusion site pain (2.9% lefamulin; 0% moxifloxacin). Infusion site phlebitis was also more common with lefamulin than moxifloxacin (Table 6 ). There was 1 patient in each treatment group who discontinued the study drug because of an infusion site reaction (phlebitis for the patient in the lefamulin group and erythema for the patient in the moxifloxacin group).
Few patients experienced a hepatobiliary organ class TEAE (0.7% lefamulin; 1.5% moxifloxacin). No liver chemistry-associated TEAE resulted in study drug discontinuation. There was 1 moxifloxacin-treated patient who met the laboratory criteria for Hy's law on Day 3 [26] , which was likely due to the patient's underlying cardiac disease. Liver chemistry test results were similar between treatment groups (Supplementary Table 2 ).
Overall incidences of cardiac disorders were comparable between treatment groups (2.9% lefamulin; 4.0% moxifloxacin). There were 8 patients (n = 3 lefamulin; n = 5 moxifloxacin) who had nonserious TEAEs of prolonged QT intervals; in 4 patients (n = 1 lefamulin; n = 3 moxifloxacin), the event led to study drug discontinuation. The overall mean (standard deviation) change from baseline in QT interval corrected according to Fridericia (QTcF) on Day 3 post-dose was 13.8 (19.8) millisecond for lefamulin and 16.4 (21.4) millisecond for moxifloxacin. No lefamulin-treated patient and 2 moxifloxacin-treated patients had a post-baseline increase of >60 millisecond that resulted in a value >480 millisecond; no patient in either group had a post-baseline increase of >60 millisecond that resulted in a value >500 millisecond.
The TEAEs leading to study drug discontinuations that affected >1 patient in either treatment group were infectious pleural effusion (n = 1 lefamulin; n = 2 moxifloxacin) and prolonged QT intervals (n = 1 lefamulin; n = 3 moxifloxacin). The serious TEAE of worsening pneumonia was reported in 5 patients (n = 4 lefamulin; n = 1 moxifloxacin). Treatment-related serious TEAEs were reported in 1.1% of lefamulin-treated patients (injection site reaction, increased liver function test, increased alanine aminotransferase) and 0.4% moxifloxacin-treated patients (angioedema). Only the case of angioedema resulted in study drug discontinuation. TEAEs resulted in 11 deaths (n = 6 lefamulin; n = 5 moxifloxacin) during the study ( Table 6) , none of which were considered by the investigator to be related to the study drug. 
DISCUSSION
This study demonstrated that efficacy of lefamulin, the first pleuromutilin for IV and oral use in humans, was noninferior to that of moxifloxacin in adults with CABP. Noninferiority was achieved for both ECR and IACR. Outcome rates were high with both agents, with observed ECR responder rates of 87.3% (lefamulin) and 90.2% (moxifloxacin) and IACR success rates of 81.7-86.9% (lefamulin) and 84.2-89.4% (moxifloxacin). Lefamulin and moxifloxacin were generally safe and well tolerated.
Lefamulin monotherapy achieved high response rates for CABP caused by S. pneumoniae, S. aureus, H. influenzae, and M. catarrhalis. Lefamulin also demonstrated efficacy against CABP caused by atypical pathogens M. pneumoniae, C. pneumoniae, and L. pneumophila. These data are consistent with previous in vitro studies demonstrating lefamulin activity against typical and atypical CABP pathogens, with its activity unaffected by resistance to other antibiotic classes [14, 16, 18] . In this study, an atypical pathogen was detected in ~17% (91/551) of all patients, consistent with published epidemiologic data [7, 27] .
Lefamulin-and moxifloxacin-treated patients reported similar TEAE rates; most were mild or moderate in severity. Gastrointestinal events and infusion site reactions, the most frequent TEAEs, were rarely treatment-limiting. Gastrointestinal events more commonly began during oral versus IV treatment with lefamulin (7.7% vs 3.7%, respectively), but more commonly began during IV versus oral treatment with moxifloxacin (12.1% vs 5.8%, respectively). Clostridium difficile infection was not reported. Hepatic aminotransferase increases were infrequent, transient, and of similar incidences in both treatment groups. The mean QTcF prolongation from baseline with IV lefamulin was numerically less than that with IV moxifloxacin; outlier QTcF values were observed only in the moxifloxacin group. The mortality rate was comparable to those reported in other randomized, controlled trials in patients with similar CABP severity indicators (ie, PORT risk class, CURB-65 [confusion of new onset, defined as blood urea nitrogen >19 mg/dL, respiratory rate ≥30 breaths/min, blood pressure <90 mmHg systolic or ≤60 mmHg diastolic, and age ≥65 years], and systemic, inflammatory response syndrome [SIRS] criteria) [28, 29] .
The strengths of this study include the exclusion of patients with milder CABP forms and the limitation on prior antibiotic use. In addition, diagnostic tests yielded a high pathogen-detection rate. The selection of moxifloxacin as an active control ensured assay sensitivity and allowed for a clinically relevant noninferiority comparison. Possible limitations include the low number of PORT risk class V patients and the few patients enrolled from North America, Western Europe, and Latin America. Planned sensitivity analyses by geographic region could not be performed.
Subpopulation analyses suggested that moxifloxacin appeared to be more efficacious than lefamulin in patients aged <65 years. A similar result was observed in patients meeting the minor ATS severity criteria [6] . The clinical significance of the ATS severity criteria findings is unknown and may reflect the effect of chance on the small ATS subpopulation, given that (1) treatment differences in efficacy were not observed across other severity indices (ie, PORT, CURB-65, SIRS criteria), (2) logistic regression models did not identify ATS variables that could explain treatment group differences, (3) there was an imbalance in study drug discontinuations before ECR assessments, for reasons apparently unrelated to efficacy (eg, withdrawal from study for adverse events or personal reasons, n = 7 lefamulin and n = 1 moxifloxacin), and (4) preliminary pharmacokinetic analyses from this study indicate no difference in lefamulin exposure in younger versus older patients. Minor ATS severity criteria were defined as the presence of ≥3 of the following at baseline: respiratory rate ≥30 breaths/min, oxygen saturation <90% or partial pressure of arterial oxygen <60 mmHg, blood urea nitrogen ≥20 mg/dL, white blood cell count <4000 cells/mm 3 , confusion, multilobar infiltrates, platelet count <100 000 cells/mm 3 , temperature <36°C, and systolic blood pressure <90 mmHg. CURB-65 criteria were defined as blood urea nitrogen >19 mg/dL, respiratory rate ≥30 breaths/min, blood pressure <90 mmHg systolic or ≤60 mmHg diastolic, and age ≥65 years. Abbreviations: ATS, American Thoracic Society; CI, confidence interval; CURB-65, confusion of new onset; ECR, early clinical response; IACR, investigator assessment of clinical response; ITT, intent-to-treat; mITT, modified ITT; NE, not evaluable due to n < 10; SIRS, systemic inflammatory response syndrome. a National Kidney Foundation categories of renal impairment were determined by Cockcroft-Gault (30) using baseline central laboratory serum creatinine. b Prior antibiotic use within 72 hours before randomization, as reported on the case report form.
An early protocol amendment changed active lefamulin treatment duration from 5 to 7 days; most patients enrolled in the lefamulin group received the longer treatment duration. This protocol change was undertaken for logistical reasons and not as a result of any interim analysis of efficacy or safety data. An analysis of clinical response rates by protocol version demonstrated comparable findings.
In conclusion, lefamulin treatment was noninferior to moxifloxacin, and both treatments were generally safe and well tolerated. Lefamulin is the first systemic antibacterial of a new antibiotic class with favorable clinical data in the treatment of CABP in >15 years. Lefamulin is an IV and oral empiric monotherapy that provides targeted antimicrobial activity against the most prevalent CABP pathogens, providing clinicians a potential CABP treatment option that aligns with the principles of antimicrobial stewardship [6] . Abbreviations: ALT, alanine aminotransferase; QTcF, QT interval corrected according to Fridericia; TEAE, treatment-emergent adverse event. a A TEAE is defined as an adverse event that starts or worsens with or after the first dose of the study drug. b Per protocol, sites were instructed to report nonserious adverse events through the testof-cure visit and serious adverse events through late follow-up. c Lefamulin (elevated liver function test, injection site reaction, and ALT increase); moxifloxacin (angioedema). d Lefamulin (ventricular arrhythmia, sepsis, congestive heart failure, myocardial infarction, pneumonia, and chronic obstructive pulmonary disease); moxifloxacin (cerebrovascular accident, testicular seminoma, hematemesis/hemorrhagic shock, cardiac arrest, and death due to natural causes). e Lefamulin (pulmonary tuberculosis, congestive heart failure, pleural empyema, infusion site phlebitis, prolonged QTcF interval, bradycardia, pneumonia, and chronic obstructive pulmonary disease); moxifloxacin (n = 3 prolonged QTcF interval, n = 2 pleural empyema, and n = 1 each for acute respiratory failure/pneumonia, hemorrhagic shock, infusion site erythema, atrial fibrillation/arterial hypertension/pulmonary embolism, confusion, angioedema, and acute cystitis). f Lefamulin (congestive heart failure, myocardial infarction, pneumonia, chronic obstructive pulmonary disease, and pleuritis); moxifloxacin (n = 2 prolonged QTcF interval and n = 1 each for pneumonia, hematemesis/hemorrhagic shock, infusion site erythema, pulmonary embolism, cardiac arrest, death due to natural causes, angioedema, atrial tachycardia/atrial fibrillation/prolonged QTcF interval, and acute cystitis).
